Raise closed, search for fresh raises on Seedstage

Beverly, MA

Advancing personalized cancer therapies through innovative RNA technology.

• Mission: Transforming cancer treatment through innovative RNA technology, focusing on personalized therapies for patients with breast and ovarian cancer.  
• Innovation: The OneRNA® platform analyzes RNA profiles to provide real-time diagnostic insights, enabling personalized treatment options and repurposing FDA-approved drugs.  
• Partnerships: Collaborating with leading institutions like Rutgers, MD Anderson, and Northwell to advance RNA therapeutics and companion diagnostics.  
• Market Opportunity: Targeting the $3 billion women’s cancer market, with plans to expand personalized treatment solutions for a broader patient population.  
• Clinical Validation: OneRNA® has been validated in breast and ovarian cancers, offering multiple treatment options and identifying suitable clinical trials for patients.  
• Growth Strategy: Seeking to accelerate the development of personalized cancer treatments and expand market reach, improving patient outcomes and quality of care.  

Genomic Expression is focused on transforming cancer treatment through its innovative RNA platform, OneRNA®, which enables personalized therapies for patients suffering from breast and ovarian cancer. The company is at the commercial stage and has successfully achieved CLIA certification, allowing it to utilize OneRNA® as a diagnostic tool for treatment navigation.

By analyzing unique RNA profiles of patients and repurposing FDA-approved drugs, Genomic Expression aims to improve patient outcomes and save lives. The company has established partnerships with prestigious institutions such as Rutgers, MD Anderson, Northwell, and the NCI, which facilitate collaborations with pharmaceutical companies to develop RNA therapeutics and companion diagnostics.

With a strong foundation built on previous funding and revenue generation, the current fundraising effort seeks to further expand its capabilities and reach within the estimated $3 billion women’s cancer market. This initiative is aimed at accelerating the development and availability of personalized cancer treatments, ultimately enhancing the quality of care for patients battling these diseases.

Company Info

Genomic Expression focuses on developing RNA-based diagnostics and therapeutics for personalized cancer treatment.

Genomic Expression is a biotechnology company that has developed the OneRNA platform, which focuses on RNA-based diagnostics and therapeutics. The platform is designed to analyze over 20,000 mRNAs in cancer tissue samples to offer personalized treatment options by repurposing approved drugs and developing novel RNA therapies. Unlike DNA-based methods, which assess disease risk, RNA analysis provides real-time information on the actual presence of disease, making it a more powerful tool for guiding treatment decisions. OneRNA has been validated in breast and ovarian cancers, offering multiple treatment options and identifying suitable clinical trials for patients. Genomic Expression is expanding its efforts to further individualize cancer treatments through RNA therapeutics.